Adding rigor to stroke rate investigations in patients with atrial brillation. Circulation. 2017;135(3):220-223. 63. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial brillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep. 2016;6:27410. 64. Chao TF, Wang KL, Liu CJ, et al. Age threshold for increased stroke risk among patients with atrial brillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol. 2015;66(12):1339- 1347. 65. Chao TF, Lip GY, Liu CJ, et al. Validation of a modi ed CHA2DS2- VASc score for stroke risk strati cation in Asian patients with atrial brillation: a nationwide cohort study. Stroke. 2016;47(10):2462- 2469. 66. Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modi er rather than a risk factor for stroke in atrial brillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation. 2018;137(8):832-840. 67. Chao TF, Lip GYH, Liu CJ, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial brillation. J Am Coll Cardiol. 2018;71(2):122-132. 68. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial brillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371(9609):315-321. 69. Fang MC, Go AS, Chang Y, et al. A New risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011;58(4):395-401. 70. Deitelzweig SB, Pinsky B, Buysman E, et al. Bleeding as an outcome among patients with nonvalvular atrial brillation in a large managed care population. Clin Ther. 2013;35(10):1536-1545.e1531. 71. Schulman S, Kearon C. De nition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. 72. 